Levothyroxine for Metabolic Dysfunction-Associated Steatohepatitis: It Is the Prime Time for Randomized Controlled Trials.
Saved in:
| Title: | Levothyroxine for Metabolic Dysfunction-Associated Steatohepatitis: It Is the Prime Time for Randomized Controlled Trials. |
|---|---|
| Authors: | Polyzos SA; Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: spolyzos@auth.gr., Yen PM; Cardiovascular and Metabolism Disorders Program, Duke-NUS Medical School, Singapore, Singapore; National Heart Centre of Singapore, Singapore; Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine and Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina., Duntas LH; Thyroid Section, Unit of Endocrinology, Diabetes and Metabolism, Evgenideion Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: lduntas@eugenideio.uoa.gr. |
| Source: | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2026 Jul; Vol. 32 (7), pp. 1170-1173. Date of Electronic Publication: 2026 Mar 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9607439 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1530-891X (Print) Linking ISSN: 1530891X NLM ISO Abbreviation: Endocr Pract Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 1530-891X |
|---|---|
| DOI: | 10.1016/j.eprac.2026.03.098 |
